SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Follow-on biologics: data exclusivity and the balance between innovation and competition
16 references·0 citing·34 second hop
Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exclusivity and…The cost of biopharmaceutical R&D: is biotech different? (2007)The cost of biopharmaceutical…Mergers and acquisitions in the pharmaceutical and biotech industries (2007)Mergers and acquisitions in t…Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Estimating The Cost Of New Dr…Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances (2005)Productivity in pharmaceutica…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001 (2003)The Impact of New Drug Launch…Measuring the Gains from Medical Research: An Economic Approach (2003)Measuring the Gains from Medi…Returns on Research and Development for 1990s New Drug Introductions (2002)Returns on Research and Devel…Technology policy for a world of skew-distributed outcomes (2000)Technology policy for a world…Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)Protecting Their Intellectual…Returns to R&D on new drug introductions in the 1980s (1994)Returns to R&D on new drug in…Industrial market structure and economic performance (1990)Industrial market structure a…Patents and innovation: an empirical study (1986)Patents and innovation: an em…Patents and Innovation: An Empirical Study (1986)Patents and Innovation: An Em…Industrial Market Structure and Economic Performance. (1971)Industrial Market Structure a…Invention, Growth and Welfare: A Theoretical Treatment of Technological Change. (1970)Invention, Growth and Welfare…Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)The Patent Paradox Revisited: An Empirical Study of Patenting in the U.S. Semiconductor Industry, 1979-1995 (2001)Absorptive Capacity: A Review, Reconceptualization, and Extension (2002)Links and Impacts: The Influence of Public Research on Industrial R&D (2002)Invention and Economic Growth (1966)Citation Frequency and the Value of Patented Inventions (1999)Technological Change and the Environment (2000)Technological change and the Environment (2003)Ideas for rent: an overview of markets for technology (2010)The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (2013)Principles of Corporate Finance. (1981)Cost of innovation in the pharmaceutical industry (1991)Deconstructing the Drug Development Process: The New Face of Innovation (2010)The cost of drug development: A systematic review (2011)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)Imitation Costs and Patents: An Empirical Study (1981)On the sources and significance of interindustry differences in technological opportunities (1995)What percentage of innovations are patented? empirical estimates for European firms (1998)Measuring innovative performance: is there an advantage in using multiple indicators? (2003)Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care (2009)The productivity crisis in pharmaceutical R&D (2011)Some Approaches to the Theory and Measurement of Total Factor Productivity: A Survey (1970)Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry (1991)Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials (2015)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Innovation, growth and survival (1995)When do firms learn from their acquisition experience? Evidence from 1990 to 1995 (2001)Fifty Years of Empirical Studies of Innovative Activity and Performance (2010)Sectoral patterns of technical change: Towards a taxonomy and a theory (1984)First-mover advantages (1988)Sources, Procedures, and Microeconomic Effects of Innovation (2000)
this work references cited by second hop

References

  • 1971Industrial Market Structure and Economic Performance.6,267 cited
  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2000Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not)3,045 cited
  • 1990Industrial market structure and economic performance2,573 cited
  • 1986Patents and Innovation: An Empirical Study1,128 cited
  • 2006Estimating The Cost Of New Drug Development: Is It Really $802 Million?906 cited
  • 1986Patents and innovation: an empirical study854 cited
  • 1970Invention, Growth and Welfare: A Theoretical Treatment of Technological Change.632 cited
  • 2000Technology policy for a world of skew-distributed outcomes625 cited
  • 2007The cost of biopharmaceutical R&D: is biotech different?517 cited
  • 2002Returns on Research and Development for 1990s New Drug Introductions311 cited
  • 2005Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances290 cited
  • 2003Measuring the Gains from Medical Research: An Economic Approach250 cited
  • 2007Mergers and acquisitions in the pharmaceutical and biotech industries236 cited
  • 2003The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

200 cited
  • 1994Returns to R&D on new drug introductions in the 1980s197 cited
  • Cited by

    No citing works inside the corpus for this window.